Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1112-1118

  Thomas, Xavier ^a   Raffoux, Emmanuel ^b   Renneville, Aline ^c   Pautas, Cécile ^d   de Botton, Stéphane ^e   de Revel, Thierry ^f   Reman, Oumedaly ^g   Terré, Christine ^h   Gardin, Claude ⁱ   Chelghoum, Youcef ^a   Boissel, Nicolas ^b   Quesnel, Bruno ^c   Cordonnier, Catherine ^d   Bourhis, Jean Henri ^e   Elhamri, Mohamed ^a   Fenaux, Pierre ⁱ   Preudhomme, Claude ^c   Socié, Gérard ^b   Michallet, Mauricette ^a   Castaigne, Sylvie ^h   Dombret, Hervé ^b   more..

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f PERCY MILITARY HOSPITAL   (France)

^g Centre de Gerontologie Georges CLEMENCEAU   (France)

^h CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Allogeneic transplantation; Chemotherapy; Prognosis; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR RUNX;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW RESCUE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ALGORITHMS; CLINICAL TRIALS AS TOPIC; FEMALE; FRANCE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864006671     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.020     Document Type: Article

References (27)

1. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Löwenberg B., Griffin J.D., Tallman M.S. Acute myeloid leukemia and acute promyelocytic leukemia. Hematol Am Soc Hematol Educ Program 2003, 82-101.
3. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
4. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000, 14:476-479.
5. Craddock C., Tauro S., Moss P., Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005, 129:18-34.
6. Breems D.A., van Putten W.L.J., Huijgens P.C., Ossenkoppele G.J., Verhoef G.E., Verdonck L.F., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
7. Giles F., O'Brien S., Cortes J., Verstovsek S., Bueso-Ramos C., Shan J., et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer 2005, 104:547-554.
8. Thomas X., Raffoux E., Botton S., Pautas C., Arnaud P., de Revel T., et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007, 21:453-461.
9. Thomas X., Raffoux E., Renneville A., Pautas C., de Botton S., Terré C., et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010, 116:1725-1732.
10. Thomas X., Elhamri M., Raffoux E., Renneville A., Pautas C., de Botton S., et al. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. Blood 2011, 118:1754-1762.
11. Castaigne S., Chevret S., Archimbaud E., Fenaux P., Bordessoulle D., Tilly H., et al. Randomized comparison of double induction and timed-sequentialinduction to a "3+7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004, 104:2467-2474.
12. Mayer R.J., Davies R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994, 331:896-903.
13. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179.
14. Byrd J.C., Dodge R.K., Carroll A., Baer M.R., Edwards C., Stamberg J., et al. Patients with t(8;21)(q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17:3767-3775.
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:626-629.
16. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Criteria for the diagnosis of acute leukemia of megacaryocyte lineage (M7): a report from the French-American-British Cooperative Group. Ann Intern Med 1985, 103:460-462.
17. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991, 78:325-329.
18. Klein J.P., Rizzo J.D., Zhang M.J., Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001, 28:909-915.
19. Schmid C., Labopin M., Nagler A., Bornhäuser M., Finke J., Fassas A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
20. Tauro C., Craddock C., Peggs K., Begum G., Mahendra P., Cook G., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387.
21. Davies S.M., Ramsay N.K., Weisdorf D.J. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant 1996, 17:737-740.
22. Biggs J.C., Horowitz M.M., Gale R.P., Ash R.C., Atkinson K., Helbig W., et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992, 80:1090-1093.
23. Schiller G., Feig S.A., Territo M., Wolin M., Lill M., Belin T., et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 1994, 88:72-78.
24. Michallet M., Thomas X., Vernant J.P., Kuentz M., Socié G., Espérou-Bourdeau H., et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000, 26:1157-1163.
25. Fung H.C., Stein A., Slovak M.L., O'Donnell M.R., Snyder D.S., Cohen S., et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003, 9:766-771.
26. Schmid C., Schleuning M., Schwerdtfeger R., Hertenstein B., Mischak-Weissinger E., Bunjes D., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
27. Eapen M., Giralt S.A., Horowitz M.M., Klein J.P., Wagner J.E., Zhang M.J., et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004, 34:721-727.